What is the average price target for NUTRIEN LTD (NTR.CA) stock?
27 analysts have analysed NTR.CA and the average price target is 78.31 CAD. This implies a price decrease of -20.6% is expected in the next year compared to the current price of 98.62.
TSX:NTR • CA67077M1086
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUTRIEN LTD (NTR.CA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-27 | OPPENHEIMER & CO., INC. | Maintains | Outperform -> Outperform |
| 2025-12-12 | Veritas Investment Research | Maintains | Buy -> Buy |
| 2022-11-17 | TD Research | Maintains | Buy |
| 2022-11-17 | Barclays | Downgrade | |
| 2022-11-07 | RBC Royalbank | Downgrade | Outperform |
| 2022-11-04 | Morningstar Inc. | Upgrade | Hold |
| 2022-11-04 | Raymond James Capital | Upgrade | Outperform |
| 2022-11-04 | TD Research | Downgrade | Buy |
| 2022-11-04 | Scotiabank Capital | Downgrade | Sector Perform |
| 2022-11-03 | Zacks Research Inc. | Maintains | Hold |
| 2022-11-03 | Scotiabank Capital | Maintains | Sector Perform |
| 2022-11-01 | Mizuho Securities | Initiate | Hold |
| 2022-11-01 | STA Research | Maintains | Underperform |
| 2022-10-31 | TD Research | Downgrade | Hold |
| 2022-08-26 | Morningstar Inc. | Downgrade | Sell |
| 2022-08-26 | STA Research | Downgrade | Underperform |
| 2022-08-09 | Scotiabank Capital | Downgrade | Outperform |
| 2022-08-05 | BMO Financial | Downgrade | Outperform |
| 2022-08-05 | Morningstar | Upgrade | Hold |
| 2022-08-04 | Scotiabank Capital | Maintains | Sector Perform |
| 2022-08-04 | STA Research | Maintains | Underperform |
| 2022-07-29 | TD Research | Downgrade | Buy |
| 2022-07-21 | Scotiabank Capital | Maintains | Sector Perform |
| 2022-07-21 | STA Research | Downgrade | Underperform |
| 2022-07-14 | Scotiabank Capital | Maintains | Sector Perform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 29.056B -23.30% | 25.972B -10.61% | 26.885B 3.52% | 26.994B 0.41% | 26.694B -1.11% | 26.731B 0.14% | 27.19B 1.72% | 28.28B 4.01% | 29.715B 5.07% | 30.356B 2.16% | 31.01B 2.15% | |
| EBITDA YoY % growth | 5.971B -49.65% | 5.288B -11.44% | 5.954B 12.59% | 6.618B 11.15% | 6.233B -5.82% | 6.178B -0.88% | 5.974B -3.30% | 6.164B 3.18% | 6.16B -0.06% | 6.255B 1.54% | 6.351B 1.53% | |
| EBIT YoY % growth | 3.802B -61.39% | 2.949B -22.44% | 3.585B 21.57% | 4.355B 21.48% | 3.922B -9.94% | 3.713B -5.33% | 3.442B -7.30% | 3.531B 2.59% | 3.588B 1.61% | 3.646B 1.62% | 3.704B 1.59% | |
| Operating Margin | 13.09% | 11.35% | 13.33% | 16.13% | 14.69% | 13.89% | 12.66% | 12.49% | 12.07% | 12.01% | 11.94% | |
| EPS YoY % growth | 4.36 -66.67% | 3.50 -19.72% | 4.56 30.29% | 5.62 23.29% | 5.07 -9.89% | 5.04 -0.50% | 4.37 -13.24% | 5.26 20.32% | 4.96 -5.76% | 5.05 1.83% | 5.15 2.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.53 379.42% | 2.89 9.01% | 0.97 0.36% | 0.91 9.75% | 0.64 21.04% | 2.95 1.95% | 0.93 -4.55% | 0.89 -1.99% |
| Revenue Q2Q % growth | 5.317B 9.09% | 10.38B 1.78% | 5.601B -2.34% | 5.226B 1.63% | 5.372B 1.03% | 10.628B 2.39% | 5.784B 3.27% | 5.309B 1.59% |
| EBITDA Q2Q % growth | 1.095B 33.54% | 2.594B -14.25% | 1.373B -47.07% | 1.293B -57.92% | 1.166B 6.48% | 2.538B -2.16% | 1.368B -0.36% | 1.297B 0.31% |
| EBIT Q2Q % growth | 496.46M 99.38% | 2.093B 13.75% | 696.12M -12.11% | 731.02M 3.84% | N/A | N/A | N/A | N/A |
All data in USD
27 analysts have analysed NTR.CA and the average price target is 78.31 CAD. This implies a price decrease of -20.6% is expected in the next year compared to the current price of 98.62.
NUTRIEN LTD (NTR.CA) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of NUTRIEN LTD (NTR.CA) is 0.53 CAD and the consensus revenue estimate is 5.32B CAD.
The consensus rating for NUTRIEN LTD (NTR.CA) is 74.8148 / 100 . This indicates that analysts generally have a positive outlook on the stock.